Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab
Authors
Keywords
-
Journal
LEUKEMIA
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-04-04
DOI
10.1038/s41375-018-0100-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Venetoclax for the treatment of chronic lymphocytic leukemia
- (2017) Massimo Gentile et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification
- (2017) Luca Laurenti et al. HAEMATOLOGICA
- Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification
- (2017) Luca Laurenti et al. HAEMATOLOGICA
- Real-world clinical experience in the Connect®chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres
- (2016) Anthony Mato et al. BRITISH JOURNAL OF HAEMATOLOGY
- Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials
- (2016) Massimo Gentile et al. EUROPEAN JOURNAL OF CANCER
- Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
- (2016) M. Winqvist et al. HAEMATOLOGICA
- Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
- (2016) HAEMATOLOGICA
- First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
- (2016) Barbara Eichhorst et al. LANCET ONCOLOGY
- Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
- (2016) M. Winqvist et al. HAEMATOLOGICA
- Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients
- (2016) HAEMATOLOGICA
- Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
- (2015) D. Rossi et al. BLOOD
- Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia
- (2015) P. A. Thompson et al. BLOOD
- Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
- (2015) K. Fischer et al. BLOOD
- Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target
- (2015) Fortunato Morabito et al. LEUKEMIA & LYMPHOMA
- Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia
- (2012) D. Rossi et al. BLOOD
- Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
- (2012) Kirsten Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now